Watkins P B
General Clinical Research Center, University of Michigan Hospital, Ann Arbor 48109-0108, USA.
Ther Drug Monit. 1996 Aug;18(4):368-71. doi: 10.1097/00007691-199608000-00009.
The intravenous 14C-erythromycin breath test (ERMBT) appears to be a convenient and reproducible means of measuring the activity of a major drug-metabolizing enzyme present in the liver, termed CYP3A4. Interpatient differences in liver CYP3A4 activity, as measured by the ERMBT, seem to account, for the most part, for interindividual differences in the kinetics of cyclosporin A and FK506. The predictability of the test may be improved as an oral form of the test and improved oral formulations of transplant medications are developed. Although the ERMBT is a promising research tool, its role in clinical transplantation has yet to be defined.
静脉注射14C-红霉素呼气试验（ERMBT）似乎是一种方便且可重复的方法，用于测量肝脏中一种主要的药物代谢酶CYP3A4的活性。通过ERMBT测量的肝脏CYP3A4活性的个体间差异，在很大程度上似乎可以解释环孢素A和FK506动力学的个体间差异。随着口服形式的该试验以及移植药物改进的口服制剂的开发，该试验的可预测性可能会提高。尽管ERMBT是一种有前景的研究工具，但其在临床移植中的作用尚未明确。
